Law firm Robbins LLP has initiated securities litigation against biopharmaceutical company uniQure N.V., asserting that the firm made materially misleading statements to investors regarding the regulatory pathway for its gene therapy candidate AMT-130. According to the complaint, the company allegedly failed to fully disclose that its Pivotal Study design had not received complete FDA approval and downplayed the risks of delays in the biologics license application (BLA) timeline.
The allegations center on investor communications issued prior to November 3, 2025, when the FDA provided feedback on the company's development program. Following that regulatory guidance, uniQure's stock price declined sharply, falling from $67.69 to $34.29—a 49% decrease—prompting the class action filing. The case seeks to recover losses incurred by shareholders who purchased securities during the period when the company's representations are alleged to have been inaccurate.
Investors who believe they were harmed by the company's disclosures must submit their claim as lead plaintiff by April 13, 2026. Class action certification requires that investors notify the court of their intent to serve as lead plaintiff within the specified timeframe. The litigation is currently in its early stages, and the allegations remain unproven.